FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969895025> ?p ?o ?g. }

• W2969895025 abstract "16074 Background: Isolated adjuvant radio- or chemotherapy (CHT) only reduces local or distant relapses in HREC without impact on overall-survival. Therefore a multicenter feasibility study on adjuvant sequential chemo- and radiotherapy of HREC was initiated in order to evaluate safety and toxicity. Planned number of patients was 40, if after 17 pts. no termination of therapy because of toxicity was necessary, study can be closed and a phase III-study can be initiated. The data on toxicity are presented. Methods: Eligibility criteria: adenocarcinomas G1/G2 stage IC or G3 stage IA-IC or all stages II and IIIA (histological), all tumours with more than 2 cm diameter in size or non endometrioid cancers stage IA-C, II and IIIA and all cases with vessel invasion. Surgery: abdominal hysterectomy with bilateral adnexectomy without lymphadenectomy or with pelvic and para-aortic lymphadenectomy and positive lymph nodes. Further: Karnofsky-Index > 70, normal bone marrow, kidney, and liver function with laboratory tests not higher than 1.5 times of the normal local reference values. CHT: 175 mg/m 2 paclitaxel plus carboplatin AUC 5, q 3 weeks for 4 cycles beginning latest 6 weeks after surgery. Within 6 further weeks after CHT an external beam irradiation (total dose 50.4 Gy, 28 fractions with 1.8 GY/d) plus 3 intracavitary HDR-iridium-192- brachytherapy courses with 3 x 5 GY were performed. Results: To date 17 pts (mean 64.1 years) completed 68 cycles CHT and following radiotherapy. There was no termination of therapy. Grade III leucopenia was observed in 9 % with 2 pts. requiring prolongation of treatment interval. There were 3 and 1 % grade II anemia and thrombocytopenia respectively. Further grade II toxicity: alopecia 38, fatigue 12, nausea/emesis 3, sensory neuropathy 12 %. Administration of G-CSF (pegfilgrastim) and epoitin (darbepoetin) was necessary in 2 and 6 % of cycles. Conclusions: Adjuvant sequential chemo- and radiotherapy of HREC is feasible by safety and toxicity and a phase III study can be initiated. No significant financial relationships to disclose." @default.
• W2969895025 created "2019-08-29" @default.
• W2969895025 creator A5002555374 @default.
• W2969895025 creator A5010293363 @default.
• W2969895025 creator A5033311059 @default.
• W2969895025 creator A5047053483 @default.
• W2969895025 creator A5076930274 @default.
• W2969895025 creator A5084015382 @default.
• W2969895025 date "2007-06-20" @default.
• W2969895025 modified "2023-10-18" @default.
• W2969895025 title "Toxicity of adjuvant sequential chemo- and radiotherapy of high-risk endometrial carcinoma (HREC)—Results of a phase II multicenter feasibility NOGGO study" @default.
• W2969895025 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.16074" @default.
• W2969895025 hasPublicationYear "2007" @default.
• W2969895025 type Work @default.
• W2969895025 sameAs 2969895025 @default.
• W2969895025 citedByCount "0" @default.
• W2969895025 crossrefType "journal-article" @default.
• W2969895025 hasAuthorship W2969895025A5002555374 @default.
• W2969895025 hasAuthorship W2969895025A5010293363 @default.
• W2969895025 hasAuthorship W2969895025A5033311059 @default.
• W2969895025 hasAuthorship W2969895025A5047053483 @default.
• W2969895025 hasAuthorship W2969895025A5076930274 @default.
• W2969895025 hasAuthorship W2969895025A5084015382 @default.
• W2969895025 hasConcept C121608353 @default.
• W2969895025 hasConcept C126322002 @default.
• W2969895025 hasConcept C126894567 @default.
• W2969895025 hasConcept C143998085 @default.
• W2969895025 hasConcept C168563851 @default.
• W2969895025 hasConcept C2777088508 @default.
• W2969895025 hasConcept C2777546739 @default.
• W2969895025 hasConcept C2777863537 @default.
• W2969895025 hasConcept C29456083 @default.
• W2969895025 hasConcept C29730261 @default.
• W2969895025 hasConcept C2992435398 @default.
• W2969895025 hasConcept C3018454096 @default.
• W2969895025 hasConcept C31760486 @default.
• W2969895025 hasConcept C509974204 @default.
• W2969895025 hasConcept C71924100 @default.
• W2969895025 hasConceptScore W2969895025C121608353 @default.
• W2969895025 hasConceptScore W2969895025C126322002 @default.
• W2969895025 hasConceptScore W2969895025C126894567 @default.
• W2969895025 hasConceptScore W2969895025C143998085 @default.
• W2969895025 hasConceptScore W2969895025C168563851 @default.
• W2969895025 hasConceptScore W2969895025C2777088508 @default.
• W2969895025 hasConceptScore W2969895025C2777546739 @default.
• W2969895025 hasConceptScore W2969895025C2777863537 @default.
• W2969895025 hasConceptScore W2969895025C29456083 @default.
• W2969895025 hasConceptScore W2969895025C29730261 @default.
• W2969895025 hasConceptScore W2969895025C2992435398 @default.
• W2969895025 hasConceptScore W2969895025C3018454096 @default.
• W2969895025 hasConceptScore W2969895025C31760486 @default.
• W2969895025 hasConceptScore W2969895025C509974204 @default.
• W2969895025 hasConceptScore W2969895025C71924100 @default.
• W2969895025 hasLocation W29698950251 @default.
• W2969895025 hasOpenAccess W2969895025 @default.
• W2969895025 hasPrimaryLocation W29698950251 @default.
• W2969895025 hasRelatedWork W151172257 @default.
• W2969895025 hasRelatedWork W2028816025 @default.
• W2969895025 hasRelatedWork W2348495938 @default.
• W2969895025 hasRelatedWork W2460868461 @default.
• W2969895025 hasRelatedWork W2461744023 @default.
• W2969895025 hasRelatedWork W2513916013 @default.
• W2969895025 hasRelatedWork W2788839829 @default.
• W2969895025 hasRelatedWork W2942848944 @default.
• W2969895025 hasRelatedWork W4206581437 @default.
• W2969895025 hasRelatedWork W4237106564 @default.
• W2969895025 isParatext "false" @default.
• W2969895025 isRetracted "false" @default.
• W2969895025 magId "2969895025" @default.
• W2969895025 workType "article" @default.